Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
26
Active, not recruiting, industry sponsors, Ophthalmology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed279
26 trials
Showing 1 to 25, recently updated first.
- Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis PigmentosaActive, not recruiting
AAVantgarde Bio SrlIndustry
NCT06591793 · 15 participants (planned) · Start Jul 2, 2024 · Primary completion Jan 2031
Drug: AAVB-081 · For: Usher Syndrome, Type 1B
Sites: Naples, Italy; London, United Kingdom · 3 sites in all
- Study Evaluating Safety & Tolerability of Migaldendranib in US Healthy VolunteersActive, not recruiting
Ashvattha Therapeutics, Inc.Industry
NCT07943221 · 24 participants (planned) · Start Aug 12, 2026 · Primary completion Oct 23, 2026
Drug: Weekly subcutaneous administration of Migaldendranib (MGB) · For: Healthy Volunteers
Sites: Cincinnati, Ohio
- Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)Active, not recruiting
Ascidian Therapeutics, IncIndustry
NCT06467344 · 15 participants (planned) · Start Jun 11, 2024 · Primary completion Aug 1, 2030
Drug: ACDN-01 · For: Stargardt Disease; Cone Rod Dystrophy; Juvenile Macular Degeneration and 1 more
Sites: San Francisco, California; Gainesville, Florida; Miami, Florida · 11 sites in all
- Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)Active, not recruiting
Luxa Biotechnology, LLCIndustry
NCT04627428 · 18 participants · Start Apr 5, 2022 · Primary completion Aug 5, 2028
Drug: RPESC-RPE-4W · For: Dry Age-related Macular Degeneration
Sites: Beverly Hills, California; Palo Alto, California; Ann Arbor, Michigan
- Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular DegenerationActive, not recruiting
Perceive Biotherapeutics, Inc.Industry
NCT06087458 · 60 participants (planned) · Start Jun 21, 2023 · Primary completion Oct 2027
Drug: VOY-101 · For: Age-Related Macular Degeneration; Geographic Atrophy; Non-neovascular AMD and 1 more
Sites: Scottsdale, Arizona; Poway, California; Sacramento, California · 16 sites in all
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular DegenerationActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02286089 · 24 participants · Start Apr 1, 2015 · Primary completion Dec 31, 2021
Drug: OpRegen · For: Age-Related Macular Degeneration
Sites: San Francisco, California; Cincinnati, Ohio; Philadelphia, Pennsylvania · 7 sites in all
- EC-104 Intravitreal Implant for the Treatment of Diabetic Macular EdemaActive, not recruiting
Eclipse Life Sciences, Inc.Industry
NCT06536491 · 75 participants (planned) · Start Aug 19, 2024 · Primary completion Oct 15, 2026
Drug: EC-104 high dose; EC-104 low dose and 1 more · For: Diabetic Macular Edema
Sites: Tampa, Florida
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06847854 · 151 participants · Start Dec 8, 2022 · Primary completion Nov 16, 2026
Drug: RO7497372 · For: Diabetic Macular Edema
Sites: Mesa, Arizona; Peoria, Arizona; Phoenix, Arizona · 38 sites in all
- Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)Pivotal-lookingActive, not recruiting
Alcon ResearchIndustry
NCT05769153 · 139 participants · Start Dec 6, 2023 · Primary completion Apr 2027
Drug: AR-14034 SR implant lower dose; AR-14034 SR implant higher dose and 3 more · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Dothan, Alabama; Gilbert, Arizona; Phoenix, Arizona · 42 sites in all
- Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital AmaurosisActive, not recruiting
OcugenIndustry
NCT05203939 · 22 participants · Start Jan 24, 2022 · Primary completion Mar 2027
Drug: OCU400 Low Dose; OCU400 Med Dose and 2 more · For: Retinitis Pigmentosa; Leber Congenital Amaurosis
Sites: Phoenix, Arizona; La Jolla, California; Miami, Florida · 7 sites in all
- A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular DegenerationActive, not recruiting
SanofiSanofi (SNY)
NCT06660667 · 66 participants (planned) · Start Nov 21, 2024 · Primary completion May 18, 2027
Drug: SAR402663; Diluent · For: Neovascular Age-related Macular Degeneration
Sites: Phoenix, Arizona; Scottsdale, Arizona; Bakersfield, California · 26 sites in all
PYC TherapeuticsIndustry
NCT06852963 · 17 participants · Start Jun 1, 2025 · Primary completion Mar 8, 2028
Drug: VP-001 · For: Retinitis Pigmentosa 11; Retinal Degeneration; Retinal Disease and 2 more
Sites: Jacksonville, Florida; Miami, Florida; Ann Arbor, Michigan · 6 sites in all
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular HypertensionPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT04499248 · 100 participants · Start Nov 16, 2020 · Primary completion Apr 2029
Drug: AGN-193408 SR; AGN-193408 SR · For: Open-angle Glaucoma; Ocular Hypertension
Sites: Sun City, Arizona; Glendale, California; Inglewood, California · 49 sites in all
- Promising ROd-cone DYstrophy Gene therapYActive, not recruiting
SparingVisionIndustry
NCT05748873 · 33 participants · Start Apr 12, 2023 · Primary completion Feb 2027
Drug: SPVN06 · For: Retinitis Pigmentosa
Sites: Miami, Florida; Boston, Massachusetts; Portland, Oregon · 6 sites in all
- Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular DegenerationActive, not recruiting
Ocugenix CorporationIndustry
NCT05904691 · 24 participants · Start Nov 1, 2023 · Primary completion Nov 30, 2026
Drug: OCU-10-C-110 for Injection · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Carmel, Indiana; Abilene, Texas; Willow Park, Texas
- A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)Active, not recruiting
Exegenesis BioIndustry
NCT06817343 · 12 participants (planned) · Start Sep 10, 2024 · Primary completion Feb 2029
Drug: Aflibercept (2.0 mg) · For: Neovascular Age-Related Macular Degeneration (nAMD); Neovascular (Wet) Age-related Macular Degeneration (AMD)
Sites: Reno, Nevada; Erie, Pennsylvania
Avirmax Biopharma IncIndustry
NCT06550011 · 18 participants (planned) · Start Aug 7, 2024 · Primary completion Jan 13, 2027
Drug: ABI-110 Low Dose; ABI-110 Medium Dose and 1 more · For: Neovascular (Wet) AMD
Sites: Bakersfield, California; Walnut Creek, California; San Antonio, Texas · 4 sites in all
- A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular DegenerationActive, not recruiting
Oxford BioMedicaIndustry
NCT01678872 · 18 participants (planned) · Start Aug 2012 · Primary completion Mar 2029
Drug: RetinoStat · For: Age-Related Macular Degeneration
Sites: Iowa City, Iowa; Baltimore, Maryland; Portland, Oregon
- A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular DegenerationActive, not recruiting
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT06825858 · 9 participants (planned) · Start Apr 7, 2025 · Primary completion Jan 2027
Drug: KH658 · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Lemont, Illinois; Memphis, Tennessee
- Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular DegenerationActive, not recruiting
Chengdu Origen Biotechnology Co., Ltd.Industry
NCT05657301 · 25 participants (planned) · Start Oct 16, 2023 · Primary completion Sep 2026
Drug: KH631 · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Lemont, Illinois; Boston, Massachusetts · 7 sites in all
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic SolutionPivotal-lookingActive, not recruiting
SpyGlass Pharma, Inc.Industry
NCT06120842 · 201 participants · Start Oct 13, 2023 · Primary completion Jan 31, 2025
Drug: Bimatoprost Implant System (High Dose); Bimatoprost Implant System (Low Dose) and 1 more · For: Cataract; Glaucoma; Ocular Hypertension
Sites: Glendale, Arizona
- 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)Active, not recruiting
4D Molecular TherapeuticsIndustry
NCT04517149 · 21 participants · Start Jun 9, 2020 · Primary completion Jun 2026
Drug: 4D-125 IVT Injection · For: X-Linked Retinitis Pigmentosa
Sites: Aurora, Colorado; Gainesville, Florida; Ann Arbor, Michigan · 8 sites in all
- Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMDActive, not recruiting
Beijing Anlong Biopharmaceutical Co., Ltd.Industry
NCT06707753 · 21 participants (planned) · Start Sep 11, 2023 · Primary completion Aug 31, 2025
Drug: AL-001 · For: Wet Age-related Macular Degeneration (wAMD)
Sites: Beijing, China
- Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsActive, not recruiting
Beacon TherapeuticsIndustry
NCT03316560 · 29 participants · Start Apr 16, 2018 · Primary completion Nov 9, 2023
Drug: rAAV2tYF-GRK1-RPGR · For: X-Linked Retinitis Pigmentosa
Sites: Durham, North Carolina; Cincinnati, Ohio; Portland, Oregon · 4 sites in all
- Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.Pivotal-lookingActive, not recruiting
Laboratoires TheaIndustry
NCT05389267 · 120 participants (planned) · Start Jul 5, 2022 · Primary completion Dec 31, 2024
Drug: Kinezodianone R hydrochloride; Placebo · For: Glaucoma; Ocular Hypertension
Sites: Glendale, California
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.